BTIG analyst Robert Hazlett reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report) on July 12 and set a price target of $3.00. The company's shares closed last Wednesday at $0.82. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 1.9% and a 37.4% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Axsome Therapeutics, and Seelos Therapeutics. Currently, the analyst consensus on Matinas BioPharma is a Strong Buy with an average price target of $3.00.
https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-matinas-biopharma-mtnb?utm_source=advfn.com&utm_medium=referral
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Matinas Biopharma Charts.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Matinas Biopharma Charts.